Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-66728
von Kempis, Johannes; Dudler, Jean; Hasler, Paul; Kyburz, Diego; Tyndall, Alan; Zufferey, Pascal; Villiger, Peter M (2012). Use of abatacept in rheumatoid arthritis. Swiss Medical Weekly, 142:w13581.
View at publisher
Abatacept (CTLA-Ig), a modulator of T-lymphocyte activation, has been approved by the Swiss health regulatory agency Swissmedic for the treatment of active rheumatoid arthritis (RA). This article summarises the key trial findings for this biologic agent in RA in different situations such as early erosive rheumatoid arthritis (RA), biologic-naïve RA, RA before and after the use of methotrexate or TNF-inhibitors and includes safety information from these trials. Based on these data, recommendations for clinical practice in Switzerland are made by a panel of experts.
45 downloads since deposited on 16 Nov 2012
28 downloads since 12 months
|Item Type:||Journal Article, refereed, further contribution|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine|
|Dewey Decimal Classification:||610 Medicine & health|
|Deposited On:||16 Nov 2012 14:28|
|Last Modified:||05 Apr 2016 16:05|
|Publisher:||EMH Swiss Medical Publishers|
|Free access at:||PubMed ID. An embargo period may apply.|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page